[1] Paget S.The distribution of secondary growths in cancer of the breast. 1889[J]. Cancer Metastasis Rev,1989,8(2):98-101.
[2] Junttila MR, de Sauvage FJ. Influence of tumour microen-vironment heterogeneity on therapeutic response[J]. Nature,2013,501(7467):346-354.
[3] Miller JF, Sadelain M.The journey from discoveries in fundamental immunology to cancer immunotherapy[J]. Cancer Cell,2015,27(4):439-449.
[4] Riaz N, Havel JJ, Makarov V, et al.Tumor and microenvironment evolution during immunotherapy with nivolu-mab[J]. Cell,2017,171(4):934-949.
[5] Thomas PD, Kahn M.Kat3 coactivators in somatic stem cells and cancer stem cells: biological roles, evolution, and pharmacologic manipulation[J]. Cell Biol Toxicol,2016,32(1):61-81.
[6] Plitas G, Konopacki C, Wu K, et al.Regulatory T cells exhibit distinct features in human breast cancer[J]. Immunity,2016,45(5):1122-1134.
[7] Nishikawa H, Sakaguchi S.Regulatory T cells in cancer immunotherapy[J]. Rinsho Ketsueki,2014,55(10):2183-2189.
[8] Zitvogel L, Tanchot C, Granier C, et al.Following up tumor-specific regulatory T cells in cancer patients[J]. Oncoimmunology,2013,2(7):e25444.
[9] Sander FE, Nilsson M, Rydström A, et al.Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy[J]. Cancer Immunol Immunother,2017,66(11):1473-1484.
[10] Qian BZ, Li J, Zhang H, et al.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis[J]. Nature,2011,475(7355):222-225.
[11] Hao NB, Lu MH, Fan YH, et al.Macrophages in tumor microenvironments and the progression of tumors[J]. Clin Dev Immunol,2012,2012:948098.
[12] Janols H, Bergenfelz C, Allaoui R, et al.A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases[J]. J Leukoc Biol,2014,96(5):685-693.
[13] Yu J, Du W, Yan F, et al.Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer[J]. J Immunol,2013,190(7):3783-3797.
[14] Ortiz ML, Lu L, Ramachandran I, et al.Myeloid-derived suppressor cells in the development of lung cancer[J]. Cancer Immunol Res,2014,2(1):50-58.
[15] Lee KW, Yeo SY, Sung CO, et al.Twist1 is a key regulator of cancer-associated fibroblasts[J]. Cancer Res,2015, 75(1):73-85.
[16] Polanska UM, Orimo A.Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells[J]. J Cell Physiol,2013,228(8):1651-1657.
[17] Olumi AF, Grossfeld GD, Hayward SW, et al.Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium[J]. Cancer Res,1999, 59(19):5002-5011.
[18] Underwood TJ, Hayden AL, Derouet M, et al.Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma[J]. J Pathol,2015,235(3):466-477.
[19] Richards KE, Zeleniak AE, Fishel ML, et al.Cancer-associated fibroblast exosomes regulate survival and proli-feration of pancreatic cancer cells[J]. Oncogene,2017,36(13):1770-1778.
[20] Palazon A, Tyrakis PA, Macias D, et al.An hIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression[J]. Cancer Cell,2017,32(5):669-683.
[21] Viallard C, Larrivee B.Tumor angiogenesis and vascular normalization: alternative therapeutic targets[J]. Angiogenesis,2017,20(4):409-426.
[22] Rofstad EK, Galappathi K, Mathiesen BS.Tumor interstitial fluid pressure - a link between tumor hypoxia, microvascular density, and lymph node metastasis[J]. Neoplasia,2014,16(7):586-594.
[23] Coley WB. II. Contribution to the knowledge of sarcoma[J]. Ann Surg,1891,14(3):199-220.
[24] McNutt M. Cancer immunotherapy[J]. Science,2013,342(6165):1417.
[25] Rosenberg SA, Packard BS, Aebersold PM, et al.Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report[J]. N Engl J Med,1988,319(25):1676-1680.
[26] Rosenberg SA, Restifo NP, Yang JC, et al.Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer,2008,8(4):299-308.
[27] Lawrence MS, Stojanov P, Polak P, et al.Mutational he-terogeneity in cancer and the search for new cancer-asso-ciated genes[J]. Nature,2013,499(7457):214-218.
[28] Ali SA, Shi V, Maric I, et al.T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood,2016,128(13):1688-1700.
[29] Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J]. Sci Transl Med, 2015,7(303):303ra139.
[30] Brown CE, Alizadeh D, Starr R, et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J]. N Engl J Med,2016,375(26):2561-2569.
[31] Xia AL, Wang XC, Lu YJ, et al.Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities[J]. Oncotarget,2017,8(52):90521-90531.
[32] Sharma P, Hu-Lieskovan S, Wargo JA, et al.Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell,2017,168(4):707-723.
[33] Schadendorf D, Hodi FS, Robert C, et al.Pooled analysis of long-term survival data from phase Ⅱ and phaseⅢ trials of ipilimumab in unresectable or metastatic melanoma[J]. J Clin Oncol,2015,33(17):1889-1894.
[34] Friedman CF, Proverbs-Singh TA, Postow MA.Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review[J]. JAMA Oncol,2016,2(10):1346-1353.
[35] Sharpe AH, Pauken KE.The diverse functions of the PD1 inhibitory pathway[J]. Nat Rev Immunol,2017,18(3):153-167.
[36] Sharma P, Allison JP.The future of immune check point therapy[J]. Science,2015,348(6230):56-61.
[37] Robert C, Schachter J, Long GV, et al.Pembrolizumab versus Ipilimumab in advanced melanoma[J]. N Engl J Med,2015,372(26):2521-2532.
[38] Pauken KE, Sammons MA, Odosizzi PM, et al.Epigene-tic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade[J]. Science,2016,354(6316):1160-1165.
[39] Luke JJ, Flaherty KT, Ribas A, et al.Targeted agents and immunotherapies: optimizing outcomes in melanoma[J]. Nat Rev Clin Oncol,2017,14(8):463-482.
[40] Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with pla-tinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial[J]. Lancet,2017,391(10122):748-757.
[41] Balar AV, Galsky MD, Rosenberg JE, et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. Lancet,2017,389(10064):67-76.
[42] Miao D, Margolis CA, Gao W, et al.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[J]. Science,2018,359(6377):801-806.
[43] Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.Over-all survival with combined nivolumab and Ipilimumab in advanced melanoma[J]. N Engl J Med,2017,377(14):1345-1356.
[44] Herrera FG, Bourhis SJ, Coukos G.Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA Cancer J Clin,2017,67(1):65-85.
[45] Lee JM, Cimino-Mathews A, Peer CJ, et al.Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women′s cancers: A dose-escalation, phaseⅠstudy[J]. J Clin Oncol,2017,35(19):2193-2202.
[46] Govindan R, Szczesna A, Ahn MJ, et al.Phase Ⅲ trial of Ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer[J]. J Clin Oncol,2017,35(30):3449-3457.
[47] Matson V, Fessler J, Bao R, et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J]. Science,2018,359(6371):104-108.
[48] Gopalakrishnan V, Spencer CN, Nezi L, et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science,2018,359(6371):97-103. |
